达巴万星单用及联合β-内酰胺类对耐药金黄色葡萄球菌的体外评价
该研究通过MIC测试和时间杀菌曲线,评估达巴万星单用及联合五种β-内酰胺类对50株不同耐药表型金黄色葡萄球菌的活性。达巴万星对全部MRSA菌株有活性,MIC50为0.0313 mg/L、MIC90为0.0625 mg/L,与多种β-内酰胺类联用可降低MIC并显示协同作用。
要点
- 达巴万星对包括hVISA、VISA、达托霉素不敏感和利奈唑胺耐药株在内的MRSA均有活性。
- 达巴万星与头孢唑林、头孢吡肟、厄他培南对全部测试菌株协同。
- 达巴万星联合β-内酰胺类对耐药金黄色葡萄球菌表型具协同作用,支持进一步评估。
核心结论
- 达巴万星对全部测试的MRSA菌株有活性,包括异质性万古霉素中介、万古霉素中介、达托霉素不敏感和利奈唑胺耐药分离株。
- 达巴万星与β-内酰胺类联用对耐药金黄色葡萄球菌表型显示协同作用,支持联合用药的进一步评估。
研究设计与样本
- 体外研究,纳入50株具有不同药敏谱的金黄色葡萄球菌分离株。
- 达巴万星单用及联合五种β-内酰胺类(头孢唑林、头孢吡肟、头孢洛林、厄他培南、苯唑西林)进行MIC测试。
- 在0.5×MIC各β-内酰胺存在下测定达巴万星MIC,并对随机选取的代表各MRSA表型的菌株进行时间杀菌曲线分析。
主要发现
- 达巴万星MIC50为0.0313 mg/L,MIC90为0.0625 mg/L。
- 与各β-内酰胺联用时,达巴万星MIC降低0至超过5个2倍稀释度。
- 时间杀菌曲线中,达巴万星与头孢唑林、头孢吡肟和厄他培南对全部菌株协同。
- 达巴万星与头孢洛林(ceftaroline)联用对除1株外的全部菌株协同。
- 达巴万星与苯唑西林联用对5/8株协同。
临床怎么用
- 针对耐药金黄色葡萄球菌表型(包括hVISA、VISA、达托霉素不敏感和利奈唑胺耐药),可考虑达巴万星联合β-内酰胺类治疗。
- 联合用药前应参考本地药敏结果,达巴万星对MRSA的MIC50为0.0313 mg/L、MIC90为0.0625 mg/L。
局限性
- 研究为体外实验,需进一步临床评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Emergence of reduced susceptibility to vancomycin warrants the development of new antimicrobial agents for the treatment of MRSA. We evaluated the activity of dalbavancin, a novel lipoglycopeptide antibiotic, both alone and combined with β-lactams, in combination MIC testing and time-kill assays against resistant phenotypes of Staphylococcus aureus. METHODS: S. aureus isolates included 50 organisms with varying susceptibility patterns. Dalbavancin was tested alone and in combination with five β-lactams: cefazolin, cefepime, ceftaroline, ertapenem and oxacillin. MIC values of the antibiotics were determined for all isolates. After initial MIC testing, dalbavancin MICs were determined in the presence of 0.5 × MIC of each β-lactam to determine the effect of each β-lactam on dalbavancin MIC. Time-kill assays were performed with dalbavancin and β-lactams tested at 0.5 × MIC for randomly selected organisms representing each MRSA phenotype. Time-kill curves were generated by plotting mean colony counts (log10 cfu/mL) versus time. RESULTS: Dalbavancin MIC50 was 0.0313 mg/L and MIC90 was 0.0625 mg/L. Dalbavancin MICs decreased by zero to greater than five 2-fold dilutions in combination with each β-lactam. In time-kill assays, dalbavancin was synergistic with cefazolin, cefepime and ertapenem against all strains and the combination of dalbavancin and ceftaroline was synergistic against all but one. The combination of dalbavancin and oxacillin was synergistic against 5/8 strains. CONCLUSIONS: Dalbavancin was active against all MRSA strains tested, including heteroresistant vancomycin-intermediate S. aureus, vancomycin-intermediate S. aureus, daptomycin-non-susceptible and linezolid-resistant isolates. The synergy demonstrated against these organisms supports the use of dalbavancin in combination with β-lactams against resistant phenotypes of S. aureus. Further evaluation is warranted.
引用
- Xhemali X, Smith JR, Kebriaei R, et al. Evaluation of dalbavancin alone and in combination with β-lactam antibiotics against resistant phenotypes of Staphylococcus aureus. J Antimicrob Chemother. 2019. PMID: 30260409. doi:10.1093/jac/dky376
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。